BioSpace News Archive

Ohh-Med, a medtech startup located in the Tiberias Industrial Zone, has developed Vertica, a medical device designed to improve the lives of thousands of men who experience erectile dysfunction (ED).

Armis Biopharma, Inc. announced today the U.S. Food and Drug Administration (FDA) has provided 510(k) clearance for the VeriCyn® Wound Wash medical device. VeriCyn® Wound Wash provides skin-friendly wound care with a unique formula that is chlorine and surfactant free.

ValnevaSE, a specialty vaccine company, announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon.

Selvita S.A., one of the largest contract research organization companies in Europe, has published a financial report for Q1 2023*.

Cambrex celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, a Belgium-based contract research organization supporting pharmaceutical companies, invitro diagnosis companies, hospitals and universities with analytical services for blood investigations and hemocompatibility testing.

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announced the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp. z o.o. Sp. k. Katowice, Poland, a leading independent laboratory in Poland.

Ostentus Therapeutics, Inc., announced that it has entered into a second Sponsored Research Agreement with City of Hope, one of the largest cancer research and treatment organizations in the United States, to conduct preclinical research on OST compounds, which could be used as future therapies for leukemia and other cancers.

BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will present two abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) congress which is being held in Hamburg, Germany from June 9 – 11, 2023.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at 4:00 p.m. ET.

Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced program updates across its allogeneic CAR T pipeline.